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Abstract 
BACKGROUND: Diabetic retinopathy (DR) is one of the complications occurs in patients with diabetes mellitus (DM) 
and is the leading cause of new onset blindness. This study aimed to determine the possible association between 
plasma homocysteine (Hcy) levels and the development and progression of DR.  
METHODS: This case-control study enrolled diabetic patients who referred for ocular consultation from the 
Diabetes Clinic of Tohid Hospital in Sanandaj, Iran, in 2013. Patients with type 2 DM (n = 156) were randomly 
assigned to evaluate the association between Hcy and DR. Participants were randomly divided into two groups; 
with or without DR. Patients in both groups were matched for confounding factors. Detection and grading of 
retinopathy was performed by indirect ophthalmoscopy and fluorescein angiography. Glycosylated hemoglobin 
(HbA1c) was measured by Enzyme-linked Immunosorbent Assay and fasting plasma Hcy levels measured by 
chromatography. Plasma Hcy more than 15 µmol/l was defined as hyperhomocysteinemia. 
RESULTS: The results showed that there were no significant differences in Hcy levels in diabetic patients with or 
without retinopathy. Also, we found that there was no association between HbA1c level and plasma Hcy. In 
addition, data analysis indicates that no association was observed between disease duration and Hcy levels. 
CONCLUSION: In conclusion, we found that there was not a significant association between plasma Hcy level and 
DR in patients with type II DM. 
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Introduction1 
Diabetic retinopathy (DR) is one of the 
complications of diabetes mellitus (DM), and the 
main cause of new onset blindness among 20-74 
years old patients in Western countries.1,2 The risk 
of blindness in diabetic patients is 25 times 
greater than non-diabetic population.1 According 
to the literature the prevalence of DR varies from 




6.7% to 35%.3,4 It has been reported that over 60% 
of patients with type II DM develop retinopathy 
within one or two decades after diagnosis.5 DR 
results from microvascular decompensation 
beginning with basement membrane thickening, 
leading to vascular occlusion and eventual 
neovascularization. The duration of diabetes, 
poor glycemic control, and hypertension (HTN) 
are documented risk factors in the development 
and progression of DR.6 DR is potentially sight 
threatening, thus the need to locate more effective 
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this problem is obvious. Finding a measurable 
risk factor may have two advantages; the 
identification of patients who are at greater risk 
and decreasing the risk of this sight threatening 
condition by lowering this risk factor, if possible. 
Recently homocysteine (Hcy) has received much 
attention. Hcy is an emerging risk factor for 
cardiovascular and non-diabetic ocular vaso-
occlusive diseases.3 Evidence has now 
accumulated showing that an elevated plasma 
Hcy concentration is a risk factor for vascular 
disease in both normal patients and those with 
renal disease. Elevated concentrations may 
induce endothelial dysfunction or abnormalities 
of coagulation factors and platelets.7,8 
Hcy is a sulfur amino acid with a free thiol 
group, not present in dietary protein. This 
amino acid is a secondary by-product of 
methionine from cysteine metabolism. The 
mechanisms of Hcy pathogenesis in vascular 
damage are unclear. High Hcy levels can cause 
endothelial damage, with increased thrombosis 
and atherosclerosis. Hyperhomocysteinemia 
has been reported in both type 1 and type 2 DM 
patients. In patients with type 2 DM, the 
relation between hyperhomocysteinemia, 
macrovascular complications and renal disease 
is not completely understood; however, a 
higher prevalence of macrovascular 
complications in diabetic patients with 
hyperhomocysteinemia is associated with a 
higher prevalence of renal disease. The 
relationship between retinopathy and Hcy has 
not been clarified. Although numerous studies 
have shown an association between Hcy and 
DR, the results, thus far, have been equivocal.9 
Some studies support the concept that the 
hyperhomocysteinemia may contribute to the 
pathogenesis of retinal microangiopathy and 
DR.10-15 According to the above studies and in 
order to find a reliable factor to predict the risk 
of developing retinopathy, in this study we 
were interested to evaluate the possible 
association between plasma Hcy level and DR 
in patients with type 2 DM. 
Materials and Methods 
This case-control study enrolled diabetic patients 
who referred for ocular consultation from the 
Diabetes Clinic of Tohid Hospital, Sanandaj, Iran, 
in 2011-2012. All examinations were carried out at 
the Department of Ophthalmology at the 
Kurdistan University of Medical Sciences. 
According to the previous studies 78 subjects 
were enrolled in each group.3 All patients 
underwent complete ocular examinations that 
included a determination of visual acuity using 
the Snellen chart, slit lamp examination, 
intraocular pressure measurement, and precise 
fundus examination with fully dilated pupils, 
using an indirect ophthalmoscope and slit lamp 
biomicroscopy with a 90 D lens. In cases where 
exact grading of the extent of retinopathy was 
possible by indirect ophthalmoscope or slit lamp 
funduscopy, we performed a fundus fluorescein 
angiography, and fundus photographs were 
taken for precise detection of any micro-
aneurysms or leaking vessels. All examinations 
were done by a physician who was blind to the 
study. The case group (n = 78) composed of those 
patients with DR, irrespective of grade. For each 
case individual, we selected a matching control 
individual from previously examined diabetic 
patients. The case and control groups were 
matched according to: age, diabetes duration, 
HTN, ischemic heart disease (IHD), 
hyperlipidemia, and smoking status (according 
to: medical records, laboratory analyses, and 
cardiologic consultation). We obtained complete 
medical histories from all participants by 
conducting interviews and reviewing medical 
records in the diabetes clinic.  
Fasting blood samples were obtained from 
all case and control subjects in the same 
manner. Hcy and glycosylated hemoglobin 
(HbA1c) serum levels were measured by 
Enzyme-linked Immunosorbent Assay and 
chromatography using Statfax and Mycocard 
devices, respectively. 
Patients who had undergone laser therapy 
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with any retinal diseases that interfered with 
the grading of DR, any patients with renal 
dysfunction whose creatinine level was ≥ 1.5 
mg/dl, and those who were taking any 
medications increased plasma Hcy levels. 
SPSS for Windows (version 18.0, SPSS Inc., 
Chicago, IL, USA) was used for statistical 
analysis. The data are expressed as the mean ± 
standard error of the mean of 78 persons per 
group. Student’s t-test, chi-square or Kruskal-
Wallis was used to analyze statistical 
significance. P values < 0.05 were considered to 
be significant in all analyses. 
The Ethics Committee at the Kurdistan 
University of Medical Sciences reviewed and 
approved the study protocol. Signed informed 
consent was obtained from each individual. 
Results 
According to table 1, patients were correctly 
matched based on age, diabetes duration, 
hyperlipidemia, IHD, HTN, and smoking status. 
Data analysis indicates that there were not any 
significant differences between case and control 
groups in mentioned criteria. 
 




Case (%)  
(n = 78) 
Control (%) 
(n = 78) P 
Hyperlipidemia 51.6 63.2 0.172 
IHD 27.6 23.1 0.516 
HTN 60.3 52.6 0.333 
Smoking 4.3 4.0 0.824 
HTN: Hypertension, IHD: Ischemic heart disease 
 
Although the HbA1c level was significantly 
higher in the case group than the control  
(P = 0.002) but the results showed that there was 
not statistical differences in Hcy level between the 
case and control groups (Table 2). Furthermore, 
our findings in tables 3 and 4 show that there is 
not a significant difference between the grade of 
retinopathy and Hcy or HbA1c levels. 
In order to find a possible association between 
diabetes disease duration and Hcy level the case 
subjects were divided into five groups including 
(i) less than 5 years, (ii) 6-10 years, (iii) 11-15 years, 
(iv) 16-20 years, and (v) more than 20 years. Data 
analysis indicated that there was no significant 
difference between disease duration and Hcy level 
(P = 0.300) (Table 5). 
 
Table 2. Comparison of plasma homocysteine and 
glycosylated hemoglobin in case and control groups 
Variables Mean ± SD P 
Homocysteine (µmol/l)  
0.190 Case 10.65 ± 4.60 
Control 9.78 ± 3.50 
HbA1c  
0.002 Case 9.44 ± 2.05 
Control 8.41 ± 1.78 
HbA1c: Glycosylated hemoglobin; SD: Standard deviation 
 
Table 3. Comparison of plasma homocysteine levels and 
retinopathy grade 
Retinopathy grade Subject Mean ± SD (Hcy) P 
Mild NPDR 15 9.73 ± 3.62 
0.481 Moderate NPDR 7 12.77 ± 2.97 Severe NPDR 31 10.33 ± 4.07 
PDR 25 11.22 ± 5.93 
Hcy: Homocysteine; SD: Standard deviation 
NPDR: Non-proliferative diabetic retinopathy 
PDR: Proliferative diabetic retinopathy 
 
Table 4. Comparison of plasma glycosylated 





Mean ± SD 
(HbA1c) P 
Mild NPDR 15 9.73 ± 1.49 
0.516 Moderate NPDR 7 12.77 ± 1.35 Severe NPDR 31 10.33 ± 2.12 
PDR 25 11.22 ± 2.33 
HbA1c: Glycosylated hemoglobin; SD: Standard deviation 
NPDR: Non-proliferative diabetic retinopathy 
PDR: Proliferative diabetic retinopathy 
 
Table 5. Comparison between plasma homocysteine 





Mean ± SD 
(Hcy) P 
0-5 8 11.17 ± 6.70 
0.300 
6-10 26 10.07 ± 3.01 
11-15 25 10.08 ± 3.74 
16-20 11 13.38 ± 7.07 
> 20 8 9.90 ± 4.78 
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Discussion 
The present study was aimed to evaluate the 
possible relationship between plasma total Hcy 
(tHcy) concentration and DR. 
Our finding indicated that there was not any 
significant association between the DR degree 
and plasma Hcy level while there was a positive 
association between the presence of retinopathy 
and the amount of HbA1c (P = 0.002). 
Furthermore, the results showed that, there was 
no association between plasma Hcy levels and 
variables such as HTN, HbA1c, IHD, age, and 
diabetes duration (except for patients older than 
70 years). 
According to the literature we found that the 
association between Hcy plasma level and DR 
data is controversy.10-15 Satyanarayana et al. 
conducted a cross-sectional case-control study to 
investigate the status of B-vitamins and Hcy in 
DR. They reported that mean plasma Hcy levels 
were found to be higher in the diabetic patients 
compared to normal subjects.16 
Lim et al. showed that Hcy concentration of 
blood plasma, vitreous and aqueous in the 
patients with DR was approximately 30% higher 
than observed in the control subjects.17 In 
addition Goldstein et al. reported that there was a 
significant elevation in Hcy levels in the non-
proliferative diabetic retinopathy and 
proliferative diabetic retinopathy groups 
compared to the control group. Their findings 
have suggested that hyperhomocysteinemia 
might be associated with DR and partially 
explained the increased risk of microvascular 
angiopathy occurs in these patients.18 
Ganapathy and colleagues used mutant mice 
with endogenously elevated Hcy levels due to a 
heterozygous deletion of the cystathionine-β-
synthase gene and examined changes in retinal 
pathology following induction of diabetes. Their 
finding showed that elevated Hcy levels hastened 
cell loss in the retinal ganglion cell layer.19 This 
was approved by Lee et al. that suggested that 
hyperhomocysteinemia caused by renal failure is 
often associated with diabetic nephropathy and 
retinopathy.20 
On the other hand, some studies indicated no 
significant differences were noted in plasma Hcy 
levels between diabetic and control groups.21,22 
Another research has shown that Hcy levels in 
diabetic patients with pre-proliferative DR were 
not higher than the healthy normal group but 
were higher in the neovascular glaucoma group.12 
In our study, patients with serum creatinine 
concentration greater than 1.5 mg/dl and those 
who were diagnosed with renal failure were 
excluded. It was a difference of our study with 
others that supported the idea of a positive 
relationship between DR and 
hyperhomocysteinemia. Therefore, we have 
concluded that in those studies renal failure acted 
as a confounding factor. In addition, Ozmen et al. 
showed that elevation of plasma tHcy 
concentration in type 2 DM is related to 
deterioration of renal function and diabetic 
nephropathy.23 Furthermore, the association 
between Hcy and severity of kidney disease has 
been reported.24 Therefore, we believe that 
retinopathy may develop simultaneously with 
nephropathy in the process of developing diabetic 
microvascular complications. 
The low plasma Hcy level in all patients in 
comparison with similar studies3,4 that may be 
related to intake regimen was one of the 
limitations of the present study. In addition, the 
main limitation of this study was the use of a 
cross-sectional design, which prevents 
determination of temporal direction and, 
therefore, of causal inference. Although 
retinopathy risk factors and the most important 
confounders of Hcy in this population 
specifically, age, sex, smoking status, and renal 
status were controlled.  
In summary, we found that there was not a 
significant correlation between plasma Hcy level 
and DR.  Nevertheless, it is necessary to perform 
more studies to clarify the possible association 
between Hcy and DR. 
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